{
  "id": 1517864,
  "title": "Lexaria Bioscience regains Nasdaq compliance, stock to remain listed",
  "url": "https://urgent.news/2026/08/17/lexaria-bioscience-regains-nasdaq-compliance-stock-to-remain-listed",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T16:46:32.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/sec-filings/lexaria-bioscience-regains-nasdaq-compliance-stock-to-remain-listed-93CH-4863738"
  },
  "original_language": "en",
  "account": "Lexaria Bioscience Corp., a Nevada-based company with its headquarters in Kelowna, Canada, has regained compliance with Nasdaq's minimum bid price requirement, according to a statement from the firm. The Nasdaq Listing Rule 5550(a)(2) mandates a minimum bid price, and Lexaria had previously received notice from the exchange regarding a deficiency in this area. However, the company has now received confirmation from the Hearings Advisor of The Nasdaq Stock Market that it is now compliant. As a result, the previously scheduled hearing regarding the deficiency has been cancelled. Lexaria's common stock will continue to be listed and traded on The Nasdaq Capital Market. The company's Form 8-K filing with the Securities and Exchange Commission (SEC) provided the details of this development.",
  "summary": null,
  "key_points": [
    "Lexaria Bioscience regains Nasdaq compliance",
    "Stock remains listed on Nasdaq Capital Market",
    "Previously scheduled deficiency hearing cancelled"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}